Efficacy of Penile Traction Therapy Using a Novel Device
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03389854 |
Recruitment Status :
Completed
First Posted : January 4, 2018
Results First Posted : August 12, 2020
Last Update Posted : August 12, 2020
|
Sponsor:
Mayo Clinic
Information provided by (Responsible Party):
Landon W. Trost, Mayo Clinic
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Factorial Assignment; Masking: Double (Investigator, Outcomes Assessor); Primary Purpose: Basic Science |
Condition |
Penile Diseases |
Interventions |
Device: RestoreX PTT - randomized and open label Device: RestoreX PTT - open label phase only |
Enrollment | 110 |
Participant Flow
Recruitment Details | |
Pre-assignment Details |
Arm/Group Title | Control Group | Penile Traction Therapy Group 1x Daily x 3 Months | Penile Traction Therapy Group 2x Daily x 3 Months | Penile Traction Therapy Group 3x Daily x 3 Months |
---|---|---|---|---|
![]() |
No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired. | Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired. | Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired. | Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired. |
Period Title: Overall Study | ||||
Started | 28 | 27 | 28 | 27 |
Completed | 27 | 21 | 23 | 19 |
Not Completed | 1 | 6 | 5 | 8 |
Baseline Characteristics
Arm/Group Title | Control Group | Penile Traction Therapy Group 1x Daily x 3 Months | Penile Traction Therapy Group 2x Daily x 3 Months | Penile Traction Therapy Group 3x Daily x 3 Months | Total | |
---|---|---|---|---|---|---|
![]() |
No treatment will be administered for the initial 3 months. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired. | Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired. | Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired. | Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired. | Total of all reporting groups | |
Overall Number of Baseline Participants | 28 | 27 | 28 | 27 | 110 | |
![]() |
[Not Specified]
|
|||||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||||
Number Analyzed | 28 participants | 27 participants | 28 participants | 27 participants | 110 participants | |
58.1 (9.7) | 56.6 (8.3) | 59.0 (6.9) | 60.0 (5.5) | 58.4 (7.8) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 28 participants | 27 participants | 28 participants | 27 participants | 110 participants | |
Female |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Male |
28 100.0%
|
27 100.0%
|
28 100.0%
|
27 100.0%
|
110 100.0%
|
|
Race and Ethnicity Not Collected
[1] Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | |
0 | ||||||
[1]
Measure Analysis Population Description: Race and Ethnicity were not collected from any participant.
|
||||||
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||||||
United States | Number Analyzed | 28 participants | 27 participants | 28 participants | 27 participants | 110 participants |
28 | 27 | 28 | 27 | 110 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Dr. Landon Trost |
Organization: | Mayo Clinic |
Phone: | 507-284-3728 |
EMail: | Trost.Landon@mayo.edu |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Landon W. Trost, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT03389854 |
Other Study ID Numbers: |
17-001283 |
First Submitted: | October 19, 2017 |
First Posted: | January 4, 2018 |
Results First Submitted: | April 23, 2020 |
Results First Posted: | August 12, 2020 |
Last Update Posted: | August 12, 2020 |